Adipose tissue release of DPP4 was shown to strongly associate with visceral fat and clinical characteristics of dysmetabolic obesity (Sell et al. 2013), and DPP4 inhibitors seem to prevent and/or improve liver steatosis (Rohrborn et al. 2015). This evidence concerns the gene DPP4 and obesity due to melanocortin 4 receptor deficiency.